Join to View Full Profile
5255 Loughboro Road, NW1st FloorWashington, DC 20016
Phone+1 202-660-6500
Fax+1 202-660-6501
Dr. Smith is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Rush Medical College of Rush University Medical CenterClass of 1998
Certifications & Licensure
DC State Medical License 2006 - 2026
VA State Medical License 2020 - 2026
MD State Medical License 2002 - 2025
NY State Medical License 2003 - 2006
PA State Medical License 1999 - 2002
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- The Johns Hopkins Hope at Hopkins Clinic: supporting the comprehensive needs of individuals with metastatic breast cancer.Vered Stearns, Ruizhe Chen, Amanda L Blackford, Elizabeth Saylor, Jill Mull
Breast Cancer Research and Treatment. 2025-04-01 - Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.Yuqing Liang, Christina L Gersch, Jennifer Lehman, N Lynn Henry, Karen Lisa Smith
Pharmacogenetics and Genomics. 2024-06-01 - Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia
Cancer. 2024-05-15
Press Mentions
Know What Your Doctors Know: Mestastatic Breast Cancer Webinar October 2018September 29th, 2018
Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid LeukemiaApril 3rd, 2017- Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in NarcolepsyMarch 15th, 2017
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
